Rohit Thummalapalli
@rohit_thum
Followers
672
Following
3K
Media
50
Statuses
891
GI medical oncologist @MSKcancercenter, prior @oslerresidency @harvardmed @yale.
New York, NY / Miami, FL
Joined July 2010
RT @quinneverett: UnitedHealthcare has dropped Memorial Sloan Kettering Cancer Center from its network, leaving 20,000 cancer patients (inc….
0
9K
0
RT @ArndtVogel: A B7H3-targeting ADC in advanced solid tumor.@NatureMedicine .🔎phase 1/1b trial, 312 pts.👉High ORR….
0
10
0
RT @Erman_Akkus: 🧬Genomic mutations in GI neuroendocrine carcinoma.@myESMO GI Oncology. ❗️13.4% is KRAS mutant ➡️ worse prognosis. ❓RAS inh….
0
24
0
RT @LaurenByersMD: Striking activity with ABBV-706 SEZ6 ADC in high grade neuroendocrine cancer (NECs) where active therapies are urgently….
0
18
0
!!! Validates a number of retrospective studies in which controlling for socioeconomic status was challenging, potentially major implications across many ICI-treated cancer types… #ASCO25.
This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
0
2
11
RT @EricTopol: The remarkable benefit of exercise was just extended to improved survival after cancer in a randomized trial @NEJM #ASCO25….
0
183
0
RT @MSKCancerCenter: 🚨 New research from @ASCO: A clinical trial led by @YJanjigianMD, Chief of Gastrointestinal Medical Oncology at MSK, h….
0
9
0
RT @NiuSanford: Come on #ASCO25, this 💯 should have been a plenary!. 7% improvement in 8-yr OS w exercise in adjuvant colon ca, greater tha….
0
77
0
Impressive activity for LBL-024 PD-L1/4-1BB bispecific in epNEC with randomized P3 in combination with first line EP planned. And great discussion by Guillem Argiles @MSKCancerCenter! #ASCO25
0
3
15
RT @MGMcNamara: More evidence of potential application for testing DLL3 expression in GEP NENs @rohit_thum following oral presentation by @….
0
3
0
RT @MSK_DeptOfMed: Posters at #ASCO25 are starting now! Medical oncologist @rohit_thum will present a study that evaluated delta-like ligan….
0
3
0
RT @MGMcNamara: @OncoThor presenting early data on alpha NET therapy #ASCO25 with discussion by @helops79 Emerging promising therapy in wel….
0
5
0
DLL3 has arrived and hopefully here to stay in extrapulmonary NECs. Promising activity for DLL3-CD3 T cell engager obrixtamig irrespective of primary site, high IHC expression (>50%) appears to be required for response. Will this be needed for other agents in this space? #ASCO25
0
3
11
Amazing #BREAKWATER data - especially with 72% access to BRAFi in SOC arm. Great start to #ASCO(GI?)25!.
You don't see survival curves like this often in colorectal cancer, let alone for BRAF mutated CRC. And Median OS: 30.3 vs. 15.1 months. Wow. What a win for our patients! #ASCO25
0
0
2
RT @PatrickHwuMD: 📢 New research out today on #TILTherapy for GI cancers. ❓Can neoantigen-specific tumor-infiltrating lymphocytes (TILs) im….
0
17
0
RT @jgschraiber: My time in industry convinced me of the importance of basic, government funded science research. It was crazy how much of….
0
133
0
Congrats @AliSchram and @alexdrilon on leading this great work supporting recent accelerated approval for zenocotuzumab in NRG1 fusion+ pancreas and lung cancers! .
0
4
22
RT @ArndtVogel: Tiragolumab in combination with atezolizumab + bevacizumab in advanced or metastatic HCC.@TheLancetOncol ..
0
43
0